{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:37:39Z","timestamp":1786981059665,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32071165; 31870895; 31171135"],"award-info":[{"award-number":["32071165; 31870895; 31171135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10787-026-02175-9","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:42:34Z","timestamp":1773067354000},"page":"2579-2591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-covalent proteasome inhibitor PI1840 suppresses osteoclastogenesis and prevents LPS-induced osteolysis in mice"],"prefix":"10.1007","volume":"34","author":[{"given":"Yehua","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyi","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"2","key":"2175_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00223-017-0349-1","volume":"102","author":"F Accardi","year":"2018","unstructured":"Accardi F, Toscani D, Costa F, Aversa F, Giuliani N (2018) The proteasome and myeloma-associated bone disease. Calcif Tissue Int 102(2):210\u2013226. https:\/\/doi.org\/10.1007\/s00223-017-0349-1","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2175_CR2","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/jcb.21553","volume":"102","author":"Z Bar-Shavit","year":"2007","unstructured":"Bar-Shavit Z (2007) The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem 102(5):1130\u20131139. https:\/\/doi.org\/10.1002\/jcb.21553","journal-title":"J Cell Biochem"},{"issue":"5","key":"2175_CR3","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.3892\/or.2019.7040","volume":"41","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen H, Xie H, Yuan S, Gao C, Yu L, Bi Z (2019) Non\u2013covalent proteasome inhibitor PI\u20131840 induces apoptosis and autophagy in osteosarcoma cells. Oncol Rep 41(5):2803\u20132817. https:\/\/doi.org\/10.3892\/or.2019.7040","journal-title":"Oncol Rep"},{"key":"2175_CR4","doi-asserted-by":"publisher","unstructured":"Ding D, Yan J, Feng G, Zhou Y, Ma L, Jin Q (2022) Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF-\u03baB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis. Int J Mol Med https:\/\/doi.org\/10.3892\/ijmm.2021.5059","DOI":"10.3892\/ijmm.2021.5059"},{"issue":"1","key":"2175_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bone.2011.02.011","volume":"49","author":"R Eastell","year":"2011","unstructured":"Eastell R, Walsh JS, Watts NB, Siris E (2011) Bisphosphonates for postmenopausal osteoporosis. Bone 49(1):82\u201388. https:\/\/doi.org\/10.1016\/j.bone.2011.02.011","journal-title":"Bone"},{"key":"2175_CR6","doi-asserted-by":"publisher","first-page":"154821","DOI":"10.1016\/j.cyto.2019.154821","volume":"125","author":"P Ethiraj","year":"2020","unstructured":"Ethiraj P, Ottinger AM, Singh T, Singh A, Haire KM, Reddy SV (2020) Proteasome inhibition suppress microgravity elevated RANK signaling during osteoclast differentiation. Cytokine 125:154821. https:\/\/doi.org\/10.1016\/j.cyto.2019.154821","journal-title":"Cytokine"},{"issue":"5","key":"2175_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2175_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev 36(4):561\u2013584. https:\/\/doi.org\/10.1007\/s10555-017-9707-8","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2175_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/156802610790725515","volume":"10","author":"E Genin","year":"2010","unstructured":"Genin E, Reboud-Ravaux M, Vidal J (2010) Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr Top Med Chem 10(3):232\u2013256. https:\/\/doi.org\/10.2174\/156802610790725515","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"2175_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J (2024) NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther 9(1):53. https:\/\/doi.org\/10.1038\/s41392-024-01757-9","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2175_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","volume":"29","author":"D Han","year":"2023","unstructured":"Han D, Wang L, Jiang S, Yang Q (2023) The ubiquitin-proteasome system in breast cancer. Trends Mol Med 29(8):599\u2013621. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.006","journal-title":"Trends Mol Med"},{"issue":"12","key":"2175_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66(12):1139\u20131146. https:\/\/doi.org\/10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"},{"key":"2175_CR13","doi-asserted-by":"publisher","unstructured":"Hienz SA, Paliwal S, Ivanovski S (2015) Mechanisms of Bone Resorption in Periodontitis. J Immunol Res 2015:615486. https:\/\/doi.org\/10.1155\/2015\/615486","DOI":"10.1155\/2015\/615486"},{"key":"2175_CR14","doi-asserted-by":"publisher","first-page":"925804","DOI":"10.3389\/fcimb.2022.925804","volume":"12","author":"JJ Ignatz-Hoover","year":"2022","unstructured":"Ignatz-Hoover JJ, Murphy EV, Driscoll JJ (2022) Targeting proteasomes in cancer and infectious disease: a parallel strategy to treat malignancies and microbes. Front Cell Infect Microbiol 12:925804. https:\/\/doi.org\/10.3389\/fcimb.2022.925804","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"2175_CR15","doi-asserted-by":"publisher","first-page":"e0262612","DOI":"10.1371\/journal.pone.0262612","volume":"17","author":"M Inoue","year":"2022","unstructured":"Inoue M, Nagai-Yoshioka Y, Yamasaki R, Kawamoto T, Nishihara T, Ariyoshi W (2022) Mechanisms involved in suppression of osteoclast supportive activity by transforming growth factor-\u03b21 via the ubiquitin-proteasome system. PLoS ONE 17(2):e0262612. https:\/\/doi.org\/10.1371\/journal.pone.0262612","journal-title":"PLoS ONE"},{"issue":"5","key":"2175_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-023-00557-4","volume":"4","author":"A Javitt","year":"2023","unstructured":"Javitt A, Shmueli MD, Kramer MP, Kolodziejczyk AA, Cohen IJ, Radomir L, Sheban D, Kamer I, Litchfield K, Bab-Dinitz E, Zadok O, Neiens V, Ulman A, Wolf-Levy H, Eisenberg-Lerner A, Kacen A, Alon M, R\u00eago AT, Stacher-Priehse E, Merbl Y (2023) The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC. Nat Cancer 4(5):629\u2013647. https:\/\/doi.org\/10.1038\/s43018-023-00557-4","journal-title":"Nat Cancer"},{"issue":"22","key":"2175_CR17","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.2174\/1381612811319220016","volume":"19","author":"J Kaffy","year":"2013","unstructured":"Kaffy J, Bernadat G, Ongeri S (2013) Non-covalent proteasome inhibitors. Curr Pharm Des 19(22):4115\u20134130. https:\/\/doi.org\/10.2174\/1381612811319220016","journal-title":"Curr Pharm Des"},{"issue":"17","key":"2175_CR18","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1074\/jbc.M113.533950","volume":"289","author":"A Kazi","year":"2014","unstructured":"Kazi A, Ozcan S, Tecleab A, Sun Y, Lawrence HR, Sebti SM (2014) Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem 289(17):11906\u201311915. https:\/\/doi.org\/10.1074\/jbc.M113.533950","journal-title":"J Biol Chem"},{"key":"2175_CR19","doi-asserted-by":"publisher","unstructured":"Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen WR, Qi J, Nara Y, Pramusita A, Kinjo R, Mizoguchi I (2020) Osteocyte-related cytokines regulate osteoclast formation and bone resorption. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms21145169","DOI":"10.3390\/ijms21145169"},{"key":"2175_CR20","doi-asserted-by":"publisher","unstructured":"Koga Y, Tsurumaki H, Aoki-Saito H, Sato M, Yatomi M, Takehara K, Hisada T (2019) Roles of cyclic amp response element binding activation in the ERK1\/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms20061346","DOI":"10.3390\/ijms20061346"},{"key":"2175_CR21","doi-asserted-by":"publisher","unstructured":"Lee K, Kim MY, Ahn H, Kim HS, Shin HI, Jeong D (2017) Blocking of the ubiquitin-proteasome system prevents inflammation-induced bone loss by accelerating M-CSF receptor c-Fms degradation in osteoclast differentiation. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms18102054","DOI":"10.3390\/ijms18102054"},{"key":"2175_CR22","doi-asserted-by":"publisher","unstructured":"Lee K, Seo I, Choi MH, Jeong D (2018) Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms19103004","DOI":"10.3390\/ijms19103004"},{"key":"2175_CR23","doi-asserted-by":"publisher","unstructured":"Li H, Wang J, Sun Q, Chen G, Sun S, Ma X, Qiu H, Liu X, Xu L, Liu M (2018) Jatrorrhizine hydrochloride suppresses RANKL-induced osteoclastogenesis and protects against wear particle-induced osteolysis. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms19113698","DOI":"10.3390\/ijms19113698"},{"key":"2175_CR24","doi-asserted-by":"publisher","unstructured":"Liu X, Diao L, Zhang Y, Yang X, Zhou J, Mao Y, Shi X, Zhao F, Liu M (2022) Piperlongumine inhibits titanium particles-induced osteolysis, osteoclast formation, and RANKL-induced signaling pathways. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms23052868","DOI":"10.3390\/ijms23052868"},{"issue":"11","key":"2175_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","volume":"23","author":"T Nakashima","year":"2012","unstructured":"Nakashima T, Hayashi M, Takayanagi H (2012) New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 23(11):582\u2013590. https:\/\/doi.org\/10.1016\/j.tem.2012.05.005","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"2175_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/jjco\/hyy108","volume":"48","author":"K Okazuka","year":"2018","unstructured":"Okazuka K, Ishida T (2018) Proteasome inhibitors for multiple myeloma. Jpn J Clin Oncol 48(9):785\u2013793. https:\/\/doi.org\/10.1093\/jjco\/hyy108","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"2175_CR27","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1021\/jm400221d","volume":"56","author":"S Ozcan","year":"2013","unstructured":"Ozcan S, Kazi A, Marsilio F, Fang B, Guida WC, Koomen J, Lawrence HR, Sebti SM (2013) Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem 56(10):3783\u20133805. https:\/\/doi.org\/10.1021\/jm400221d","journal-title":"J Med Chem"},{"issue":"4","key":"2175_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/jbm.a.35978","volume":"105","author":"J Pajarinen","year":"2017","unstructured":"Pajarinen J, Lin TH, Nabeshima A, J\u00e4msen E, Lu L, Nathan K, Yao Z, Goodman SB (2017) Mesenchymal stem cells in the aseptic loosening of total joint replacements. J Biomed Mater Res A 105(4):1195\u20131207. https:\/\/doi.org\/10.1002\/jbm.a.35978","journal-title":"J Biomed Mater Res A"},{"issue":"11","key":"2175_CR29","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.jfma.2021.04.027","volume":"120","author":"X Pan","year":"2021","unstructured":"Pan X, Li X (2021) Bisphosphonates on mortality and cardiovascular risk. J Formos Med Assoc 120(11):2044\u20132045. https:\/\/doi.org\/10.1016\/j.jfma.2021.04.027","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"2175_CR30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park J, Cho J, Song EJ (2020) Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res 43(11):1144\u20131161. https:\/\/doi.org\/10.1007\/s12272-020-01281-8","journal-title":"Arch Pharm Res"},{"issue":"2","key":"2175_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000431091","volume":"62","author":"P Pietschmann","year":"2016","unstructured":"Pietschmann P, Mechtcheriakova D, Meshcheryakova A, F\u00f6ger-Samwald U, Ellinger I (2016) Immunology of osteoporosis: a mini-review. Gerontology 62(2):128\u2013137. https:\/\/doi.org\/10.1159\/000431091","journal-title":"Gerontology"},{"key":"2175_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2014.01.022","volume":"76","author":"K Scarbaci","year":"2014","unstructured":"Scarbaci K, Troiano V, Micale N, Ettari R, Tamborini L, Di Giovanni C, Cerchia C, Grasso S, Novellino E, Schirmeister T, Lavecchia A, Zappal\u00e0 M (2014) Identification of a new series of amides as non-covalent proteasome inhibitors. Eur J Med Chem 76:1\u20139. https:\/\/doi.org\/10.1016\/j.ejmech.2014.01.022","journal-title":"Eur J Med Chem"},{"key":"2175_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.drup.2015.06.001","volume":"21\u201322","author":"K Selvaraju","year":"2015","unstructured":"Selvaraju K, Mazurkiewicz M, Wang X, Gullbo J, Linder S, D\u2019Arcy P (2015) Inhibition of proteasome deubiquitinase activity: A strategy to overcome resistance to conventional proteasome inhibitors? Drug Resist Updat 21\u201322:20\u201329. https:\/\/doi.org\/10.1016\/j.drup.2015.06.001","journal-title":"Drug Resist Updat"},{"key":"2175_CR34","doi-asserted-by":"publisher","first-page":"778078","DOI":"10.3389\/fimmu.2021.778078","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Li J, Xie X, Gu F, Sui Z, Zhang K, Yu T (2021) Macrophage-osteoclast associations: origin, polarization, and subgroups. Front Immunol 12:778078. https:\/\/doi.org\/10.3389\/fimmu.2021.778078","journal-title":"Front Immunol"},{"issue":"1","key":"2175_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00774-020-01191-1","volume":"39","author":"H Takayanagi","year":"2021","unstructured":"Takayanagi H (2021) RANKL as the master regulator of osteoclast differentiation. J Bone Min Metab 39(1):13\u201318. https:\/\/doi.org\/10.1007\/s00774-020-01191-1","journal-title":"J Bone Min Metab"},{"issue":"4","key":"2175_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.bbamcr.2016.01.010","volume":"1863","author":"G Thacker","year":"2016","unstructured":"Thacker G, Kumar Y, Khan MP, Shukla N, Kapoor I, Kanaujiya JK, Lochab S, Ahmed S, Sanyal S, Chattopadhyay N, Trivedi AK (2016) Skp2 inhibits osteogenesis by promoting ubiquitin-proteasome degradation of Runx2. Biochim Biophys Acta 1863(4):510\u2013519. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.01.010","journal-title":"Biochim Biophys Acta"},{"key":"2175_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/bonekey.2015.80","volume":"4","author":"C Thouverey","year":"2015","unstructured":"Thouverey C, Caverzasio J (2015) Focus on the p38 MAPK signaling pathway in bone development and maintenance. Bonekey Rep 4:711. https:\/\/doi.org\/10.1038\/bonekey.2015.80","journal-title":"Bonekey Rep"},{"key":"2175_CR38","doi-asserted-by":"publisher","unstructured":"Tominari T, Matsumoto C, Tanaka Y, Shimizu K, Takatoya M, Sugasaki M, Karouji K, Kasuga U, Miyaura C, Miyata S, Itoh Y, Hirata M, Inada M (2024) Roles of toll-like receptor signaling in inflammatory bone resorption. Biology (Basel) https:\/\/doi.org\/10.3390\/biology13090692","DOI":"10.3390\/biology13090692"},{"issue":"1","key":"2175_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00774-020-01162-6","volume":"39","author":"N Udagawa","year":"2021","unstructured":"Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, Kobayashi Y, Furuya Y, Yasuda H, Fukuda C, Tsuda E (2021) Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Min Metab 39(1):19\u201326. https:\/\/doi.org\/10.1007\/s00774-020-01162-6","journal-title":"J Bone Min Metab"},{"key":"2175_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-pathmechdis-031521-040919","volume":"18","author":"DJ Veis","year":"2023","unstructured":"Veis DJ, O\u2019Brien CA (2023) Osteoclasts, master sculptors of bone. Annu Rev Pathol 18:257\u2013281. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-040919","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"2175_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","volume":"17","author":"SE Verbrugge","year":"2015","unstructured":"Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G (2015) Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther 17(1):17. https:\/\/doi.org\/10.1186\/s13075-015-0529-1","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2175_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/1389450120666190821161259","volume":"21","author":"T Wang","year":"2020","unstructured":"Wang T, He C (2020) TNF-\u03b1 and IL-6: the link between immune and bone system. Curr Drug Targets 21(3):213\u2013227. https:\/\/doi.org\/10.2174\/1389450120666190821161259","journal-title":"Curr Drug Targets"},{"key":"2175_CR42","doi-asserted-by":"publisher","unstructured":"Wang J, Fang Y, Fan RA, Kirk CJ (2021) Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms222111595","DOI":"10.3390\/ijms222111595"},{"key":"2175_CR44","doi-asserted-by":"publisher","first-page":"1021714","DOI":"10.3389\/fphar.2022.1021714","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu Z, Li X, Chen X, He X, Chen Y, Zhang L, Li Z, Yang M, Yuan G, Shi B, Chen N, Li N, Feng H, Zhou M, Rui G, Xu F, Xu R (2022) Phosphatidyl inositol 3-kinase (PI3K)-inhibitor CDZ173 protects against LPS-induced osteolysis. Front Pharmacol 13:1021714. https:\/\/doi.org\/10.3389\/fphar.2022.1021714","journal-title":"Front Pharmacol"},{"key":"2175_CR45","doi-asserted-by":"publisher","first-page":"914288","DOI":"10.3389\/fcell.2022.914288","volume":"10","author":"L Yuan","year":"2022","unstructured":"Yuan L, Li P, Zheng Q, Wang H, Xiao H (2022) The ubiquitin-proteasome system in apoptosis and apoptotic cell clearance. Front Cell Dev Biol 10:914288. https:\/\/doi.org\/10.3389\/fcell.2022.914288","journal-title":"Front Cell Dev Biol"},{"key":"2175_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","volume":"86","author":"M Zangari","year":"2016","unstructured":"Zangari M, Suva LJ (2016) The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone 86:131\u2013138. https:\/\/doi.org\/10.1016\/j.bone.2016.02.019","journal-title":"Bone"},{"issue":"2","key":"2175_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41401-019-0289-6","volume":"41","author":"XZ Zeng","year":"2020","unstructured":"Zeng XZ, Zhang YY, Yang Q, Wang S, Zou BH, Tan YH, Zou M, Liu SW, Li XJ (2020) Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4\/TRAF6 and PLC\u03b31-Ca(2+)-NFATc1 signaling pathway. Acta Pharmacol Sin 41(2):229\u2013236. https:\/\/doi.org\/10.1038\/s41401-019-0289-6","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"2175_CR48","doi-asserted-by":"publisher","first-page":"e0263839","DOI":"10.1371\/journal.pone.0263839","volume":"17","author":"H Zhang","year":"2022","unstructured":"Zhang H, Li X, Liu J, Lin X, Pei L, Boyce BF, Xing L (2022) Proteasome inhibition-enhanced fracture repair is associated with increased mesenchymal progenitor cells in mice. PLoS ONE 17(2):e0263839. https:\/\/doi.org\/10.1371\/journal.pone.0263839","journal-title":"PLoS ONE"},{"issue":"3","key":"2175_CR49","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/j.cpcardiol.2022.101536","volume":"48","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Huang S, Xie B, Zhang N, Liu Z, Tse G, Liu T (2023) Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy. Curr Probl Cardiol 48(3):101536. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101536","journal-title":"Curr Probl Cardiol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02175-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02175-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:08:13Z","timestamp":1776316093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02175-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02175-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal experiments were approved by the Experimental Committee of Nanjing Normal University (IACUC-2020065, approved date: July 15, 2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}